Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
290 GBX | -1.69% | -7.94% | -17.73% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 95.12 | 556.7 | 1,034 | 541 | 466 | 384 | - | - |
Enterprise Value (EV) 1 | 83.31 | 526.9 | 778.7 | 313.6 | 297.7 | 211 | 241.3 | 268.8 |
P/E ratio | -7.21 x | -42.4 x | -48.6 x | -23 x | -12.1 x | -7.39 x | -8.81 x | -9.19 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 4.4 x | 21.3 x | 30.5 x | 12.2 x | 11.3 x | 11.2 x | 8.44 x | 6.15 x |
EV / Revenue | 3.85 x | 20.1 x | 23 x | 7.09 x | 7.21 x | 6.17 x | 5.3 x | 4.3 x |
EV / EBITDA | -7.06 x | -52.6 x | -44.7 x | -12.7 x | -6.75 x | -4.15 x | -5.7 x | - |
EV / FCF | - | - | -53.7 x | -9.43 x | -11.7 x | -3.42 x | -4.15 x | -3.8 x |
FCF Yield | - | - | -1.86% | -10.6% | -8.53% | -29.2% | -24.1% | -26.3% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 57,389 | 77,185 | 101,203 | 102,230 | 103,860 | 104,519 | - | - |
Reference price 2 | 1.658 | 7.213 | 10.21 | 5.292 | 4.487 | 3.674 | 3.674 | 3.674 |
Announcement Date | 4/21/20 | 4/20/21 | 3/22/22 | 3/15/23 | 3/12/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 21.62 | 26.17 | 33.89 | 44.26 | 41.29 | 34.22 | 45.52 | 62.46 |
EBITDA 1 | -11.81 | -10.01 | -17.42 | -24.79 | -44.13 | -50.8 | -42.36 | - |
EBIT 1 | -12.42 | -11.06 | -18.19 | -27.36 | -48.3 | -59.54 | -51.84 | -58.85 |
Operating Margin | -57.44% | -42.25% | -53.66% | -61.82% | -116.98% | -173.98% | -113.89% | -94.22% |
Earnings before Tax (EBT) 1 | -12.9 | -11.82 | -19.08 | -23.57 | -37.92 | -50.02 | -44.14 | -44.7 |
Net income 1 | -12.9 | -11.82 | -19.08 | -23.57 | -37.92 | -51.86 | -45.38 | -44.72 |
Net margin | -59.64% | -45.15% | -56.3% | -53.25% | -91.85% | -151.53% | -99.69% | -71.6% |
EPS 2 | -0.2300 | -0.1700 | -0.2100 | -0.2300 | -0.3700 | -0.4971 | -0.4171 | -0.4000 |
Free Cash Flow 1 | - | - | -14.51 | -33.26 | -25.39 | -61.7 | -58.09 | -70.68 |
FCF margin | - | - | -42.82% | -75.14% | -61.49% | -180.3% | -127.63% | -113.16% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 4/21/20 | 4/20/21 | 3/22/22 | 3/15/23 | 3/12/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 10.89 | 10.14 | 10.15 | 11.59 | 9.608 | 10.64 | 12.42 | 8.576 | 9.043 | 8.004 | 15.67 | 7.508 | 8.131 | 8.925 | 9.658 | 10.29 |
EBITDA 1 | - | -2.077 | -4.538 | -3.672 | -8.191 | -7.085 | -5.842 | -12.22 | -12.05 | -12.87 | -6.993 | -13.08 | -12.8 | -12.53 | -12.36 | -12.31 |
EBIT 1 | - | -2.443 | -4.955 | -4.159 | -8.739 | -7.712 | -6.75 | -13.18 | -13.07 | -13.95 | -8.095 | -15.6 | -15.19 | -14.48 | -14.29 | -12.31 |
Operating Margin | - | -24.09% | -48.81% | -35.89% | -90.96% | -72.46% | -54.33% | -153.65% | -144.58% | -174.31% | -51.67% | -207.73% | -186.86% | -162.26% | -147.91% | -119.59% |
Earnings before Tax (EBT) 1 | - | - | - | -4.067 | -8.26 | -6.434 | -4.809 | -10.88 | -10.51 | -11.25 | -5.277 | -13.18 | -12.76 | -12.18 | -11.86 | - |
Net income 1 | - | -2.68 | -4.874 | -4.067 | -8.26 | -6.434 | -4.809 | -10.88 | -10.51 | -11.25 | -5.277 | -13.65 | -13.27 | -12.6 | -12.35 | -10.46 |
Net margin | - | -26.44% | -48.01% | -35.1% | -85.97% | -60.45% | -38.71% | -126.88% | -116.25% | -140.57% | -33.68% | -181.83% | -163.25% | -141.22% | -127.86% | -101.62% |
EPS 2 | -0.1000 | -0.0300 | -0.0500 | -0.0400 | -0.0800 | -0.0600 | -0.0500 | -0.1100 | -0.1000 | -0.1100 | -0.0500 | -0.1257 | -0.1243 | -0.1171 | -0.1157 | -0.0950 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 9/21/20 | 11/10/21 | 3/22/22 | 5/9/22 | 8/10/22 | 11/9/22 | 3/15/23 | 5/10/23 | 8/9/23 | 11/8/23 | 3/12/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 11.8 | 29.8 | 255 | 227 | 168 | 173 | 143 | 115 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | -14.5 | -33.3 | -25.4 | -61.7 | -58.1 | -70.7 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 1.27 | 2.07 | 3.83 | 18.5 | 3.7 | 5.5 | 6 | 6.08 |
Capex / Sales | 5.88% | 7.92% | 11.31% | 41.75% | 8.96% | 16.07% | 13.18% | 9.73% |
Announcement Date | 4/21/20 | 4/20/21 | 3/22/22 | 3/15/23 | 3/12/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.73% | 384M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+1.48% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- MXCT Stock
- Financials MaxCyte, Inc.